Regeneron Pharmaceuticals, Inc.
George L Sing (Director) sells REGN shares
AI-generated summary
Director George L Sing sold 2,000 shares of common stock in open-market transactions between November 16, 2026, and November 17, 2026, at an average price of $958.97 for a total value of $1,917,945.02. Following these transactions, the reporting person directly held 23,147 shares.
Key facts
- Insider
- George L Sing · Director
| Date | Transaction | Shares | Price | Value | Held after | Ownership |
|---|---|---|---|---|---|---|
| Nov 16, 2026 | S · open-market saleFootnotes F1 | −1,000 | $960.26 | $960,260.00 | 24,147 | Direct |
| Nov 17, 2026 | S · open-market sale | −176 | $956.96 | $168,424.96 | 23,971 | Direct |
| Nov 17, 2026 | S · open-market saleFootnotes F2 | −359 | $957.49 | $343,738.91 | 23,612 | Direct |
| Nov 17, 2026 | S · open-market saleFootnotes F3 | −465 | $958.11 | $445,521.15 | 23,147 | Direct |
Footnotes
- F1 Represents volume-weighted average price of sales of 1,000 shares of Company stock on November 16, 2026 at prices ranging from $960.00 to $960.42. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2026 at each separate price.
- F2 Represents volume-weighted average price of sales of 359 shares of Company stock on November 17, 2026 at prices ranging from $957.24 to $957.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
- F3 Represents volume-weighted average price of sales of 465 shares of Company stock on November 17, 2026 at prices ranging from $958.01 to $958.13. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
More REGN filings
- S-8
Filed Nov 19, 2026
- 4
Filed Nov 18, 2026
- 4
Filed Nov 18, 2026
- 144
Filed Nov 17, 2026
- 144
Filed Nov 17, 2026
- 144
Filed Nov 16, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.